These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19369120)

  • 21. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
    Garcia M; Weppler D; Mittal N; Nishida S; Kato T; Tzakis A; Ruiz P
    Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.
    Dalakas MC; Rakocevic G; Schmidt J; Salajegheh M; McElroy B; Harris-Love MO; Shrader JA; Levy EW; Dambrosia J; Kampen RL; Bruno DA; Kirk AD
    Brain; 2009 Jun; 132(Pt 6):1536-44. PubMed ID: 19454532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.
    Thompson B; Corris P; Miller JA; Cooper RG; Halsey JP; Isaacs JD
    J Rheumatol; 2008 Oct; 35(10):2080-2. PubMed ID: 18843768
    [No Abstract]   [Full Text] [Related]  

  • 24. Abrogation of the alloreactive responses of cadaveric donor intestinal lymphocytes by intraoperative Campath-1H exposure.
    Mathew JM; Defaria W; Kato T; Blomberg B; Carreno M; Santiago S; Weppler D; Esquenazi V; Miller J; Tzakis AG
    Transplant Proc; 2005 Mar; 37(2):1375-8. PubMed ID: 15848725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
    Thursky KA; Worth LJ; Seymour JF; Miles Prince H; Slavin MA
    Br J Haematol; 2006 Jan; 132(1):3-12. PubMed ID: 16371014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy.
    Hill P; Gagliardini E; Ruggenenti P; Remuzzi G
    Nephrol Dial Transplant; 2005 Aug; 20(8):1741-4. PubMed ID: 15870227
    [No Abstract]   [Full Text] [Related]  

  • 27. Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients.
    Nishida S; Levi DM; Moon JI; Madariaga JR; Kato T; Selvaggi G; Tryphonopoulos P; DeFaria W; Santiago S; Gaynor J; Weppler D; Martinez E; Ruiz P; Tzakis AG
    Transplant Proc; 2006; 38(6):1747-9. PubMed ID: 16908270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tight junctions and compositionally related junctional structures in mammalian stratified epithelia and cell cultures derived therefrom.
    Langbein L; Grund C; Kuhn C; Praetzel S; Kartenbeck J; Brandner JM; Moll I; Franke WW
    Eur J Cell Biol; 2002 Aug; 81(8):419-35. PubMed ID: 12234014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab.
    Ghobrial IM; Otteman LA; White WL
    N Engl J Med; 2003 Dec; 349(26):2570-2; discussion 2570-2. PubMed ID: 14695424
    [No Abstract]   [Full Text] [Related]  

  • 30. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
    Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.
    Hill QA; Hill A; Collyns TA; Pearce RM; Cook G
    Bone Marrow Transplant; 2008 Apr; 41(8):749-51. PubMed ID: 18195685
    [No Abstract]   [Full Text] [Related]  

  • 32. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.
    Stilgenbauer S; Döhner H
    N Engl J Med; 2002 Aug; 347(6):452-3. PubMed ID: 12167696
    [No Abstract]   [Full Text] [Related]  

  • 34. Remission induced by Campath-1H for thymoma-associated agranulocytosis.
    Alvares CL; Svasti-Salee D; Rowley M; Gordon-Smith EC; Marsh JC
    Ann Hematol; 2004 Jun; 83(6):398-400. PubMed ID: 14689236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes.
    Schnitzer TJ; Yocum DE; Michalska M; Balius R; Snider ME; Hays A; Thurmond LM; Johnston JM
    J Rheumatol; 1997 Jun; 24(6):1031-6. PubMed ID: 9195505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients.
    Knechtle SJ
    Pediatr Transplant; 2004 Apr; 8(2):106-12. PubMed ID: 15049789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab.
    Ravandi F; O'Brien S
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe diarrhoea during Campath-1H treatment for refractory cutaneous T-cell lymphoma.
    Goteri G; Rupoli S; Tassetti A; Pulini S; Morichetti D; Filosa A; Mandolesi A; Veccia S; Leoni P; Bearzi I
    Ann Hematol; 2006 Sep; 85(9):617-9. PubMed ID: 16821018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.